September 7, 2011 -- Shanghai Fosun Pharmaceutical (Group) and Lonza Group of Switzerland will form a generic drug JV with 100 million RMB ($15.6 million) in capital. The JV will take advantage of the strengths of each parent: Lonza in APIs and intermediates; Fosun in finishing and China distribution. The JV will be owned equally by the two partners. More details....
Stock Symbols: (SHE: 600196) (VTX: LONN)
